Publications by authors named "D Pouessel"
Article Synopsis
- Avelumab is a treatment approved for patients with advanced urothelial carcinoma (aUC) who did not experience disease progression after platinum-based chemotherapy, based on findings from the JAVELIN Bladder 100 trial.
- The AVENANCE study included 595 patients and assessed the effectiveness and safety of avelumab as a maintenance therapy, revealing a median overall survival of 21.3 months.
- The results demonstrated that avelumab is effective in this patient population, reinforcing its role in managing aUC in real-world settings.
Background: Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed.
Objectives: To evaluate the prognostic impact of lymph node (LN)-density on disease-specific survival (DSS) in patients with bladder cancer (BC) undergoing RC with pelvic lymph node dissection.
Methods: We analyzed a multi-institutional cohort of 1169 patients treated with upfront RC for cT1-4aN0M0 urothelial BCat nine centers.
Purpose: Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2-directed antibody drug conjugate with a hydrolysable linker and a potent SN-38 payload. This study explored Trop-2 expression in tumors treated with SG in cohorts 1 to 3 (C1-3) from the TROPHY-U-01 study and evaluated whether efficacy was associated with Trop-2 expression.
View Article and Find Full Text PDFWhat Is This Summary About?: Sacituzumab govitecan (brand name: TRODELVY) is a new treatment being studied for people with a type of bladder cancer, called urothelial cancer, that has progressed to a locally advanced or metastatic stage. Locally advanced and metastatic urothelial cancer are usually treated with platinum-based chemotherapy. Metastatic urothelial cancer is also treated with immune checkpoint inhibitors.
View Article and Find Full Text PDFBackground: This Phase 1b/2 study assessed the efficacy in terms of objective response rate (ORR) of the FGFR1/2/3 kinase inhibitor derazantinib as monotherapy or in combination with atezolizumab in patients with metastatic urothelial cancer (mUC) and FGFR1-3 genetic aberrations (FGFR1-3GA).
Methods: This multicenter, open-label study comprised 5 substudies. In Substudies 1 and 5, patients with mUC with FGFR1-3GA received derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5).